Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension in Pregnancy
Interventions: Mindfulness training; Behavioral
Lead sponsor: Lifespan; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Eye Diseases, Visual Impairment, Glaucoma
Interventions: Standard optometric examination, Technology enhanced eye disease detection protocol; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: HIV/AIDS, Diabetes Mellitus, Type 2, Hypertension
Interventions: Medication optimization intervention; Other
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Fort Worth, Texas

Conditions: Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions: Chlorthalidone, Lisinopril, Amlodipine, Doxazosin; Drug
Lead sponsor: Donna Arnett, 257-5678; Other
Eligibility: 55 Years and older
Enrollment: 37,939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Severe Preeclampsia, Eclampsia Preeclampsia
Interventions: Levetiracetam, magnesium sulfate; Drug
Lead sponsor: Nebraska Methodist Health System; Other
Eligibility: 19 Years and older · Female only
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Primary Aldosteronism, Hypertension
Interventions: Eplerenone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: iPSC; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension, Diabetes Mellitus
Interventions: Self-monitoring-nurse-primary care provider feedback loop; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Medication Adherence
Interventions: Increasing Medication Adherence through Physician Incentives and Messaging; Other
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 65 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Hypertension (HTN), Obesity &Amp; Overweight, Sedentary
Interventions: MIND HIIT; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 74 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension, Cardiovascular Disease
Interventions: Home Blood Pressure Monitor Group; Other
Lead sponsor: New York City Department of Health and Mental Hygiene; Government
Eligibility: 18 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Brooklyn, New York • New York, New York • The Bronx, New York

Conditions: Cardiovascular Disease
Interventions: ALT-711 (alagebrium chloride); Drug
Lead sponsor: Synvista Therapeutics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Primary Open Angle Glaucoma
Interventions: Dietary supplements - Nicotinamide and Pyruvate, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 35 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Palo Alto, California • New York, New York

Conditions: Hypertension
Interventions: Geneticure Panel for HTN therapy, JNC-8; Drug
Lead sponsor: Geneticure, LLC; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Andover, Minnesota • Blaine, Minnesota • Bloomington, Minnesota + 12 more

Conditions: Pulmonary Arterial Hypertension
Interventions: rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 28
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: inhaled mosliciguat, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more

Conditions: Hypertensive Disorder of Pregnancy
Interventions: Usual Care, Thriving Hearts; Other · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years and older
Enrollment: 17,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension, Medication Adherence
Interventions: Text Message, Behavior Economic Incentive; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: High Blood Pressure
Interventions: Whey Protein, Soy Protein, Control (carbohydrate); Dietary Supplement
Lead sponsor: United States Department of Agriculture (USDA); Federal
Eligibility: 28 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Open Angle Glaucoma
Interventions: Suprachoroidal Dissection Instrument (SDI); Device
Lead sponsor: iScience Interventional Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Apparent Mineralocorticoid Excess Syndrome
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Not listed
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Hypertension
Interventions: Induced Stress, Buccal Swab; Behavioral · Procedure
Lead sponsor: Augusta University; Other
Eligibility: 15 Years to 19 Years
Enrollment: 1,099 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Chronic Kidney Disease, Hypertension
Interventions: Group-based Care; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Mindfulness & Mechanisms Study

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

Impact of Providing Medical Records in a Patient-Centered, Community Pharmacy Based, HIV Care Model (HIV-MOI)

Genetics of Hypertension Associated Treatments (GenHAT)

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study

CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes

Increasing Medication Adherence Through Physician Incentives and Messaging

Mediterranean-DASH Intervention for Neurodegenerative Delay and High-Intensity Interval Training in Adults With Hypertension

Evaluation of Integrating Self Blood Pressure Monitoring Into Urban Primary Care Practices

STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study

Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Thriving Hearts: Healing-Centered, Integrated, Community Maternity Care

Behavioral Economics to Improve Antihypertensive Therapy Adherence

Effect of Whey Protein on Blood Pressure

Surgical Treatment of Refractory Open Angle Glaucoma

Natural History of Apparent Mineralocorticoid Excess Syndrome

Evaluating the Relationship Between Inflammation, Genetics, and Stress in the Development of High Blood Pressure

Group-based Chronic Kidney Disease Care